As Warner-Lambert stock hit new records in January, company people, including chief financial officer Ernest Larini, sold company shares valued at $11.9 million. W-L shares have soared about 17%, despite lackluster earnings, ever since Pharmacia & Upjohn announced their merger plans last August.
While the options-related trades came amid speculation that the company is a takeover target, analysts feel the "insider" share sales could be an indication that such a move is not imminent. David Saks of Gruntal & Co questioned why, if the rumors "were so hot and close and employees knew of it," they would be selling. If a takeover were close, an internal auditing commission at the company "would put a muzzle on any insider trading," he added.
A company spokesman said the "insider-share sales" were not unusual, and that company employees periodically exercise their options. All these people exercised options to buy shares at a discount, and sold them at market value. Most of the sales were done on January 2, when the company closed at a record $98.50.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze